---
title: "Dr. Reddy’s Laboratories Schedules Board Meeting for Financial Results Review"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/258379600.md"
description: "Dr. Reddy’s Laboratories has scheduled a Board meeting on October 24, 2025, to review its unaudited financial results for Q3 2025. The trading window will be closed from September 24 to October 26, 2025, to comply with SEBI regulations. The latest analyst rating for RDY stock is a Buy with a $16.00 price target. Spark’s AI Analyst rates RDY as Outperform, highlighting strong financial health but challenges in the U.S. generics market. The company, based in Hyderabad, India, focuses on affordable pharmaceuticals and has a market cap of $12.51B."
datetime: "2025-09-22T13:57:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258379600.md)
  - [en](https://longbridge.com/en/news/258379600.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258379600.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/258379600.md) | [English](https://longbridge.com/en/news/258379600.md)


# Dr. Reddy’s Laboratories Schedules Board Meeting for Financial Results Review

Dr Reddy’s Laboratories ( (RDY) ) just unveiled an update.

Dr. Reddy’s Laboratories has announced a Board meeting scheduled for October 24, 2025, to review and approve the company’s unaudited financial results for the quarter ending September 30, 2025. In compliance with SEBI regulations, the company will close its trading window from September 24 to October 26, 2025, to prevent insider trading. This announcement is significant for stakeholders as it outlines the company’s commitment to transparency and regulatory compliance, which may impact investor confidence and market performance.

The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

**Spark’s Take on RDY Stock**

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

Dr Reddy’s Laboratories exhibits strong financial health and strategic growth initiatives, which are offset by challenges in the U.S. generics market and declining gross profit margins. The technical analysis suggests stability, while the valuation is fair. The earnings call provided a mixed outlook, balancing growth with market challenges.

To see Spark’s full report on RDY stock, click here.

**More about Dr Reddy’s Laboratories**

Dr. Reddy’s Laboratories Limited is a pharmaceutical company based in Hyderabad, India. It is involved in the manufacturing and marketing of a wide range of pharmaceutical products and services, focusing on providing affordable and innovative medicines to patients worldwide.

**Average Trading Volume:** 1,205,021

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** $12.51B

Learn more about RDY stock on TipRanks’ Stock Analysis page.

### 相關股票

- [Dr Reddys Laboratories (RDY.US)](https://longbridge.com/zh-HK/quote/RDY.US.md)

## 相關資訊與研究

- [Dr. Reddy’s Head-Europe Generics Patrick Rudolf Aghanian files initial beneficial ownership statement](https://longbridge.com/zh-HK/news/281404959.md)
- [India gets cheap GLP-1 drugs: What you must know before trying it](https://longbridge.com/zh-HK/news/280274694.md)
- [Here's How Much $100 Invested In abrdn Physical Silver Shares ETF 10 Years Ago Would Be Worth Today](https://longbridge.com/zh-HK/news/281394387.md)
- [Destiny Tech100 Stock Rises After SpaceX IPO Rumors](https://longbridge.com/zh-HK/news/281415250.md)
- [BREAKINGVIEWS-SpaceX IPO will gauge market moxie more than depth](https://longbridge.com/zh-HK/news/281406751.md)